Wang Jinfeng, Zhang Xin, Wang Lili, Dong Zhaogang, Du Lutao, Yang Yongmei, Guo Yuan, Wang Chuanxin
Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, Shandong Province, China.
Department of Clinical Laboratory, Linyi People's Hospital, Linyi, Shandong Province, China.
J Surg Oncol. 2015 Jun;111(8):992-9. doi: 10.1002/jso.23937. Epub 2015 May 14.
We aimed to investigate potential of urinary cell-free microRNA-214 (miR-214) as a noninvasive biomarker for bladder cancer in this report.
We screened miR-214 expression in medium from 2 bladder cancer cell lines to determine whether it is secretory. Then we validated expression of cell-free miR-214 in urine samples from an independent set of 192 preoperative bladder cancer patients, 80 matching postoperative patients and 169 healthy controls.
miR-214 was secreted from bladder cancer cell lines. Cell-free miR-214 levels were significantly attenuated in preoperative urine from bladder cancer patients, whereas its expression significantly increased in matched postoperative urine. Underexpressed extracellular miR-214 in urine was significantly associated with higher tumor stage, higher lymph node status, higher grade, age and history of non-muscle-invasive bladder cancer (NMIBC). Urinary cell-free miR-214 could forcefully differentiate bladder cancer (area under the curve; AUC = 0.838; 95% CI = 0.796-0.875) patients from healthy controls. Additionally, miR-214 in urine supernatant could serve as an independent prognostic predicator of recurrence-free survival (RFS) and overall survival (OS) for patients with muscle-invasive bladder cancer (MIBC).
Urinary cell-free miR-214 is a hopeful biomarker for tumor stratification, early diagnosis and prognostic assessment of bladder cancer.
在本报告中，我们旨在研究尿游离微小RNA-214（miR-214）作为膀胱癌非侵入性生物标志物的潜力。
我们筛选了2种膀胱癌细胞系培养基中miR-214的表达，以确定其是否具有分泌性。然后，我们在192例术前膀胱癌患者、80例匹配的术后患者和169例健康对照的独立尿液样本中验证了游离miR-214的表达。
miR-214从膀胱癌细胞系中分泌。膀胱癌患者术前尿液中游离miR-214水平显著降低，而在匹配的术后尿液中其表达显著增加。尿液中细胞外miR-214表达不足与更高的肿瘤分期、更高的淋巴结状态、更高的分级、年龄以及非肌层浸润性膀胱癌（NMIBC）病史显著相关。尿游离miR-214能够有效地区分膀胱癌患者（曲线下面积；AUC = 0.838；95% CI = 0.796 - 0.875）与健康对照。此外，尿液上清液中的miR-214可作为肌层浸润性膀胱癌（MIBC）患者无复发生存期（RFS）和总生存期（OS）的独立预后预测指标。
尿游离miR-214是一种有望用于膀胱癌肿瘤分层、早期诊断和预后评估的生物标志物。
